It must be emphasized that GPPs are not an alternative to evidence-based recommendations. The following measures have/will be undertaken Bioactive Compound Library to disseminate and aid implementation of the guidelines: E-publication on the BHIVA website and the journal HIV Medicine. Publication in HIV Medicine. Shortened version detailing concise summary of recommendations. E-learning module accredited for CME. Educational slide set to support local and regional educational meetings. National BHIVA audit programme. The guidelines will be next fully updated and revised in 2014. However, the Writing

Group will continue to meet regularly to consider new information from high-quality studies and publish amendments and addendums to the current recommendations before the full revision date where this is thought to be clinically important to ensure continued best clinical practice. The primary aim of ART is the prevention of the mortality and morbidity associated with chronic HIV infection at low cost of drug toxicity. Treatment should improve the physical and psychological well-being of people living with HIV infection. Bortezomib solubility dmso The effectiveness and tolerability of ART has improved significantly

over the last 15 years. The overwhelming majority of patients attending HIV services in the UK and receiving ART experience long-term virological suppression and good treatment outcomes [5], which compare very favourably with other developed countries. Recent data have shown that life expectancy in the UK of someone living with HIV infection has improved significantly over recent years but is still about 13 years less than that of the UK population Olopatadine as a whole [6]. For someone aged 20 years starting ART, life expectancy increased from 30.0 to 45.8 years from 1996–1999 to 2006–2008. The impact of starting ART late is large, with up to 15 years of reduced life expectancy if ART is started later than the

current BHIVA guidelines recommend. Other data have shown that for HIV-positive men who have sex with men living in a developed country with extensive access to HIV care and assuming a high rate of HIV diagnosis, the projected life expectancy was 75 years [7]. The authors concluded that the greatest risk of excess mortality is due to delays in HIV diagnosis. Decreasing late diagnosis, starting ART earlier at recommended CD4 cell count levels, maintaining patients in care and reducing long-term drug toxicity and non-AIDS co-morbidities are crucial to further improving life expectancy and the well-being of people living with HIV infection. A further aim of treatment is the reduction in sexual transmission of HIV and for some patients may be the primary aim. The use of ART to prevent mother-to-child transmission is universally accepted and best practice is addressed in the BHIVA guidelines for the management of HIV infection in pregnant women [8].